Multiple myeloma (MM) remains a complex and heterogeneous hematologic malignancy with evolving therapeutic challenges. In recent years, immunotherapy has ...

In a new study published in Cancer Immunology Research, scientists at the Icahn School of Medicine at Mount Sinai have ...

In this valuable study, the authors provide a simple yet elegant approach to identifying therapeutic targets that synergize to prevent therapeutic resistance in ovarian cancer using cell lines, ...

Fragile X disorders include two distinct conditions: fragile X syndrome (the most common single-gene cause of developmental ...